By Harbour BioMed

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI , Nov. 7, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova , a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, announced a strategic collaboration in artificial intelligence (AI).

See Full Page